| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Platelet Factor 4 (58-70), human targets heparin and heparin-like molecules through its major heparin-binding domain. PF-4 is a chemokine released from platelet alpha-granules that binds to heparin with high affinity. The 58-70 fragment contains the major heparin-binding domain of PF-4. Through this interaction, the peptide can modulate heparin activity and heparin-dependent processes. The peptide is not sufficient to fully exert the anti-angiogenic activity of full-length PF-4, suggesting that additional regions of PF-4 are required for full biological activity.
|
|---|---|
| ln Vitro |
In vitro studies have characterized Platelet Factor 4 (58-70), human as a polypeptide comprising the 58-70 amino acid sequence of PF-4. The peptide contains the major heparin-binding domain of PF-4. However, it is insufficient to fully exert the anti-angiogenic activity of full-length PF-4. This suggests that the peptide retains heparin-binding activity but lacks other functional domains required for full biological activity. The peptide is used in studies of heparin binding and PF-4 biology. Its activity in heparin-binding assays has been confirmed.
|
| ln Vivo |
In vivo studies of Platelet Factor 4 (58-70), human are not extensively reported. As a peptide based on the heparin-binding domain of PF-4, it could be used to modulate heparin activity in vivo. However, the peptide is primarily used as a research tool for in vitro studies of heparin binding and PF-4 biology. Specific in vivo efficacy data are not available. The compound is not intended for therapeutic use. Its utility is in understanding the structure-function relationships of PF-4 and its heparin-binding domain.
|
| Enzyme Assay |
The in vitro binding assay for Platelet Factor 4 (58-70), human involves assessing the peptide's interaction with heparin or heparin-like molecules. The peptide is incubated with immobilized heparin or in solution with heparin, and binding is measured using surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), or fluorescence-based assays. The peptide's heparin-binding affinity is compared to full-length PF-4. Competition assays using heparin or heparinase can confirm specificity. Data analysis using appropriate binding models yields affinity constants. The peptide's inability to fully exert anti-angiogenic activity is confirmed in angiogenesis assays.
|
| Cell Assay |
In vitro cellular assays for Platelet Factor 4 (58-70), human are conducted using endothelial cells or other cell types to assess the peptide's effects on angiogenesis and heparin binding. Cells are treated with the peptide, and angiogenesis is assessed using tube formation assays, migration assays, or proliferation assays. The peptide's ability to inhibit angiogenesis is compared to full-length PF-4. Heparin-binding studies can be performed by adding heparin to the cultures and assessing the effects. Cell viability and specificity are confirmed using appropriate controls. The peptide's insufficient anti-angiogenic activity has been demonstrated.
|
| Animal Protocol |
In vivo animal studies for Platelet Factor 4 (58-70), human are not extensively reported. As a peptide fragment of PF-4, it could be evaluated in animal models of angiogenesis or thrombosis. However, specific published studies are not available. The peptide is primarily used as a research tool for in vitro studies of heparin binding and PF-4 biology. Its utility is in understanding the structure-function relationships of PF-4 and its heparin-binding domain.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Platelet Factor 4 (58-70), human are not applicable as the compound is a peptide research tool rather than a therapeutic candidate. The peptide has a molecular weight of 1572.97 g/mol and a molecular formula of C76H133N17O18. As a peptide, it would be susceptible to proteolytic degradation and rapid clearance if administered in vivo. It is not intended for in vivo administration. For in vitro use, it is typically dissolved in aqueous buffers. The compound is for research use only.
|
| Toxicity/Toxicokinetics |
Toxicology data for Platelet Factor 4 (58-70), human are not applicable as the compound is a peptide research tool rather than a therapeutic compound. The peptide is not administered to animals or humans for therapeutic purposes. Standard safety precautions for handling peptides should be followed. No specific toxicity data are available. The compound is for research use only and is not intended for human therapeutic applications.
|
| References | |
| Additional Infomation |
Platelet Factor 4 (58-70), human is a polypeptide comprising the 58-70 amino acid sequence of human Platelet Factor 4 (PF-4). It contains the major heparin-binding domain of PF-4 but is insufficient to fully exert the anti-angiogenic activity of full-length PF-4. The peptide has a molecular formula of C76H133N17O18 and a molecular weight of 1572.97 g/mol. It is used as a research tool for studying heparin binding, angiogenesis, and platelet biology. The peptide is for research use only and is not intended for therapeutic applications.
|
| Molecular Formula |
C76H133N17O18
|
|---|---|
| Molecular Weight |
1573.01
|
| Exact Mass |
1572
|
| CAS # |
82989-21-7
|
| PubChem CID |
11513719
|
| Appearance |
White to off-white solid powder
|
| LogP |
7.013
|
| Hydrogen Bond Donor Count |
21
|
| Hydrogen Bond Acceptor Count |
23
|
| Rotatable Bond Count |
57
|
| Heavy Atom Count |
111
|
| Complexity |
2920
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)(NC(=O)[C@H](CC(C)C)NC([C@H]1NCCC1)=O)CC1C=CC(O)=CC=1
|
| InChi Key |
SACBPCXTLNEHGC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C76H133N17O18/c1-11-46(9)62(74(108)86-53(24-15-19-35-79)66(100)82-52(23-14-18-34-78)67(101)88-58(40-45(7)8)71(105)89-56(38-43(3)4)70(104)85-55(31-32-61(96)97)68(102)91-60(42-94)76(110)111)93-75(109)63(47(10)12-2)92-69(103)54(25-16-20-36-80)83-65(99)51(22-13-17-33-77)84-73(107)59(41-48-27-29-49(95)30-28-48)90-72(106)57(39-44(5)6)87-64(98)50-26-21-37-81-50/h27-30,43-47,50-60,62-63,81,94-95H,11-26,31-42,77-80H2,1-10H3,(H,82,100)(H,83,99)(H,84,107)(H,85,104)(H,86,108)(H,87,98)(H,88,101)(H,89,105)(H,90,106)(H,91,102)(H,92,103)(H,93,109)(H,96,97)(H,110,111)
|
| Chemical Name |
4-[[2-[[2-[[6-amino-2-[[6-amino-2-[[2-[[2-[[6-amino-2-[[6-amino-2-[[3-(4-hydroxyphenyl)-2-[[4-methyl-2-(pyrrolidine-2-carbonylamino)pentanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-[(1-carboxy-2-hydroxyethyl)amino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6357 mL | 3.1786 mL | 6.3572 mL | |
| 5 mM | 0.1271 mL | 0.6357 mL | 1.2714 mL | |
| 10 mM | 0.0636 mL | 0.3179 mL | 0.6357 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
